Abstract
Metabolomics and metabolic flux analysis (MFA) are powerful tools in the arsenal of methodologies of systems biology. Currently, metabolomics techniques are applied routinely for biomarker determination. However, standard metabolomics techniques only provide static information about absolute or relative metabolite amounts. The application of stable-isotope tracers has opened up a new dimension to metabolomics by providing dynamic information of intracellular fluxes and, by extension, enzyme activities. In the first part of the manuscript we review experimental and computational technologies applicable for metabolomics analyses. In the second part we present current technologies based on the use of stable isotopes and their applications to the analysis of cellular metabolism. Beginning with the determination of mass isotopomer distributions (MIDs), we review technologies for metabolic flux analysis (MFA) and conclude with the presentation of a new methodology for the non-targeted analysis of stable-isotope labeled metabolomics data.
Keywords: Metabolomics, metabolic flux analysis, mass isotopomer distribution, GC/MS, LC/MS, stable isotope, metabolite, quenching of metabolism, Nanostructure-Initiator Mass Spectrometry (NIMS), high performance liquid chromatography
Current Pharmaceutical Biotechnology
Title: Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics
Volume: 12 Issue: 7
Author(s): Karsten Hiller, Christian Metallo and Gregory Stephanopoulos
Affiliation:
Keywords: Metabolomics, metabolic flux analysis, mass isotopomer distribution, GC/MS, LC/MS, stable isotope, metabolite, quenching of metabolism, Nanostructure-Initiator Mass Spectrometry (NIMS), high performance liquid chromatography
Abstract: Metabolomics and metabolic flux analysis (MFA) are powerful tools in the arsenal of methodologies of systems biology. Currently, metabolomics techniques are applied routinely for biomarker determination. However, standard metabolomics techniques only provide static information about absolute or relative metabolite amounts. The application of stable-isotope tracers has opened up a new dimension to metabolomics by providing dynamic information of intracellular fluxes and, by extension, enzyme activities. In the first part of the manuscript we review experimental and computational technologies applicable for metabolomics analyses. In the second part we present current technologies based on the use of stable isotopes and their applications to the analysis of cellular metabolism. Beginning with the determination of mass isotopomer distributions (MIDs), we review technologies for metabolic flux analysis (MFA) and conclude with the presentation of a new methodology for the non-targeted analysis of stable-isotope labeled metabolomics data.
Export Options
About this article
Cite this article as:
Hiller Karsten, Metallo Christian and Stephanopoulos Gregory, Elucidation of Cellular Metabolism Via Metabolomics and Stable-Isotope Assisted Metabolomics, Current Pharmaceutical Biotechnology 2011; 12 (7) . https://dx.doi.org/10.2174/138920111795909096
DOI https://dx.doi.org/10.2174/138920111795909096 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Shedding Light on Serum Vitamin D Concentrations and the Risk of Rarer Cancers
Anti-Cancer Agents in Medicinal Chemistry Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Omega-3 and Renal Function in Older Adults
Current Pharmaceutical Design Synthetic Survey and Activity of 2'-deoxy-methanocarba Nucleosides
Current Organic Synthesis Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Current Pharmaceutical Biotechnology Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Current Topics in Medicinal Chemistry New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Review of Childhood Obesity (Balar Athidhoola Rogam) in Traditional Siddha Indian Medicine
Current Traditional Medicine Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry High Concentrations of Organochlorines in a Patient with Kidney Cancer and Anorexia-cachexia Syndrome
Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Inhibitors of the Sphingosine Kinase Pathway as Potential Therapeutics
Current Cancer Drug Targets Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets Ethnomedicinal Survey of Indigenous Flora for the Management of Cancer in South-Western, Nigeria
Current Traditional Medicine Emerging Role of Apelin as a Therapeutic Target in Cancer: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Targeting Angiogenesis in Head and Neck Cancer
Current Cancer Drug Targets